BioTuesdays

Author - Leonard Zehr

Albireo Pharma Logo
Markets

Ladenburg starts Albireo Pharma at buy

Ladenburg Thalmann initiated coverage of Albireo Pharma (NASDAQ:ALBO) with a “buy” rating and $40 price target. The stock closed at $20.28 on Feb. 15. Albireo is focused on the development of novel bile acid modulators...

February 16, 2017
microbix
Developments

Microbix posts 84% jump in Q1 revenue

Microbix Biosystems (TSX:MBX) reported that revenue rose 84% to almost $2-million for the first quarter ended Dec. 31, 2016, from $1.1-million a year earlier. Strong growth in Asian markets and increased sales to the...

February 14, 2017
Feature

In conversation with Chiara Russo

By Len Zehr As a specialty pharmaceuticals analyst with Cantor Fitzgerald for the past 2 1/2 years, Chiara Russo covers developmental-stage companies that are on the cusp of changing the medical landscape as we know it...

February 14, 2017
IntelGenx Logo
Developments

IntelGenx, Tetra in development term sheet

IntelGenx (TSX-V:IGX; OTCQX:IGXT) and Tetra Bio-Pharma (CSE:TBP; OTC: GRPOF) announced the signing of a binding term sheet for the development and commercialization of a drug product containing dronabinol. Under the...

February 9, 2017
Feature

IntelGenx sees 2017 milestones as transformational

By Len Zehr IntelGenx (OTCQX:IGXT; TSX-V:IGX) has multiple milestones on tap this year with its oral film drug delivery platform, VersaFilm, as it continues building strategic partnerships in the pharmaceutical industry...

February 7, 2017
Aurinia Pharmaceuticals
Executive Moves

Richard Glickman adds CEO title at Aurinia

Richard Glickman, founder and chairman of Aurinia Pharmaceuticals (NASDAQ:AUPH; TSX:AUP), was named to the added post of CEO. The board also accepted the resignation of Charles Rowland as CEO and an executive member of...

February 7, 2017
Feature

Iridex MicroPulse probes glaucoma continuum of care

By Len Zehr Iridex’s (NASDAQ:IRIX) flagship Cyclo G6 platform for the treatment of glaucoma utilizes a proprietary method of delivering laser therapy, known as MicroPulse, and disposable probes across the continuum of...

January 31, 2017
Feature

BioTime leading advances in regenerative medicine

By Len Zehr BioTime (NYSE:MKT, TASE:BTX) has multiple data milestones scheduled this year in its two lead regenerative medicine programs: OpRegen in dry AMD and Renevia in facial aesthetics. “We believe we are one of...

January 24, 2017